文献速递炎症性肠病

乌帕替尼诱导儿童克罗恩病缓解:一项国际多中心回顾性研究

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study.
PubMed 文献 · Aliment Pharmacol Ther · 2025-02-08

这项国际多中心回顾性研究纳入100例既往生物制剂治疗失败的儿童克罗恩病患者,评估乌帕替尼诱导治疗8周的有效性与安全性。结果显示临床应答率75%、临床缓解率56%、无激素及 Exclusive Enteral Nutrition 临床缓解率52%,24例出现不良事件,最常见为痤疮。

要点

  • 乌帕替尼诱导8周时临床应答75%、临床缓解56%、无激素及全肠内营养临床缓解52%。
  • 68%患者C反应蛋白正常化,58%患者粪钙卫蛋白<150 mcg/g。
  • 24例记录不良事件,最常见为痤疮12例,2例因严重痤疮和高甘油三酯血症停药。

核心结论

  • 乌帕替尼是难治性儿童克罗恩病的有效诱导治疗,但疗效需与潜在不良事件风险权衡。

研究设计与样本

  • 2022年至2024年间在ESPGHAN IBD兴趣组和Porto组附属的全球30个中心开展的多中心回顾性研究。
  • 纳入100例儿童(中位年龄15.8岁,四分位距14.3-17.2),均既往接受过生物制剂治疗,其中89例使用过≥2种生物制剂。
  • 记录诱导后第8周的人口学、临床和实验室数据及不良事件,主要结局按意向治疗(ITT)原则分析。

主要发现

  • 8周诱导结束时,临床应答、临床缓解和无激素及全肠内营养临床缓解(CFR)分别为75%、56%和52%。
  • 诱导结束时68%患者C反应蛋白正常化,58%患者粪钙卫蛋白(FC)<150 mcg/g。
  • 8周时有可用数据的31例儿童中13例达到CFR联合FC缓解(占ITT人群13%)。
  • 24例儿童记录不良事件,最常见为痤疮12例;严重痤疮和高甘油三酯血症2例不良事件导致停药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are scarce data available on upadacitinib in children with Crohn's disease (CD). AIM: To evaluate the effectiveness and safety of upadacitinib as an induction therapy in paediatric CD. METHODS: This was a multicentre retrospective study between 2022 and 2024 of children treated with upadacitinib for induction of remission of active CD conducted in 30 centres worldwide affiliated with the IBD Interest and Porto group of the ESPGHAN. We recorded demographic, clinical and laboratory data and adverse events (AEs) at week 8 post-induction. The analysis of the primary outcome was based upon the intention-to-treat (ITT) principle. RESULTS: We included 100 children (median age 15.8 [interquartile range 14.3-17.2]). All were previously treated with biologic therapies including 89 with ≥ 2 biologics. At the end of the 8-week induction period, we observed clinical response, clinical remission and corticosteroid- and exclusive enteral nutrition-free clinical remission (CFR) in 75%, 56% and 52%, respectively. By the end of induction, 68% had achieved normalisation of C-reactive protein, and 58% had faecal calprotectin (FC) < 150 mcg/g. There was combined CFR and FC remission in 13/31 children with available data at 8 weeks (13% of the ITT population). AEs were recorded in 24 children; the most frequent was acne in 12. Two AEs (severe acne and hypertriglyceridemia) led to discontinuation of therapy. CONCLUSION: Upadacitinib is an effective induction therapy for refractory paediatric CD. Efficacy should be weighed against the potential risks of AEs.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Cohen S, Spencer EA, Dolinger MT, et al. Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study. Aliment Pharmacol Ther. 2025. PMID: 39921898. doi:10.1111/apt.70016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。